Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 9/20 | 0.65 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.54 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.54 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.54 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.54 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.51 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137138 | 1.00 | NT5E (0.65) | NT5EP2RY1ENPP1P2RY12P2RX1 | |
| SCHEMBL21136888 | 0.99 | NT5E (0.64) | NT5EP2RY1ENPP1P2RY12P2RX1 | |
| SCHEMBL21136126 | 0.99 | NT5E (0.64) | NT5EP2RY1ENPP1P2RY12P2RX1 | |
| SCHEMBL21136500 | 0.94 | NT5E (0.68) | NT5EP2RY1P2RY11RNASELIMPDH2 | |
| SCHEMBL21137137 | 0.94 | NT5E (0.68) | NT5EP2RY1P2RY11RNASELIMPDH2 | |
| SCHEMBL21136499 | 0.92 | NT5E (0.55) | NT5EP2RY1ENPP1P2RY12P2RX1 | |
| SCHEMBL21136168 | 0.91 | P2RY1 (0.58) | NT5EP2RY1ENPP1P2RY12P2RX1 | |
| SCHEMBL21136283 | 0.91 | P2RY1 (0.58) | NT5EP2RY1ENPP1P2RY12P2RX1 | |
| SCHEMBL21137143 | 0.91 | P2RY1 (0.56) | NT5EP2RY1ENPP1P2RY12P2RX1 | |
| SCHEMBL21136167 | 0.91 | P2RY1 (0.59) | NT5EP2RY1ENPP1P2RY12P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | NT5E 90/4885P2RY1 147/4885ENPP1 256/4885 |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | NT5E 92/4885P2RY1 144/4885ENPP1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.